Subscribe

Daewoong pharmaceutical Co.,Ltd (069620.KS)

KRW122,500.00 -10,000.00 (-7.55%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address 12, Bongeunsa-ro 114-gil 135-715
Seoul, KR
CEO Chang-Jae Lee
Website daewoong.com
IPO 2005-09-29
ISIN KR7069620003

Explore sections of this company profile

Description

Established in 1945 and headquartered in Seoul, South Korea, Daewoong Pharmaceutical Co., Ltd. is a global entity dedicated to the research, production, and international distribution of a diverse range of pharmaceutical products. Its extensive portfolio provides therapeutic solutions across numerous health disciplines, including treatments for central nervous system disorders, endocrine conditions, musculoskeletal ailments, nephrological issues, oncology, cardiovascular diseases, gastrointestinal complaints, and metabolic dysfunctions. The company further offers products addressing viral infections, pain relief, antacids, digestive problems, wound care, and nutritional supplements such as iron and multivitamins. Complementing its pharmaceutical offerings, Daewoong also supplies medical devices, notably COVID-19 PCR and IgG/IgM RDT diagnostic kits, along with viral transport media.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
KRW122,500.00 -10,000.00 (-7.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
34.6K
Beta
0.01
Float Shares
4.45M
Free Float %
38.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.84% -5.29% -11.94% -25.92% -25.92% -21.33% -17.71% +16.92% -14.92% +30.60% +718.62%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
122,500.00
DCF (Unlevered) 1,327,820.86 +983.9%
DCF (Levered) 288,600.06 +135.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 6 +1
Buy 5 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.11
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +10.4% ★ Q1'26: +6.0% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +691.7% ★ Q1'26: +18.3% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +7.0% Q1'26: -15.1% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +12.5% Q1'26: +5.9% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +10.9% ★ Q1'26: +3.5% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.7% Q1'26: +0.7% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    3.37× Q1'26: 5.90× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.07) × ERP
WACC = 65% × Ke + 35% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 1,353,089.59 Current price: 122,500.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
5 Rev. Ana.
6 EPS Ana. 		Dec 2027
7 Rev. Ana.
6 EPS Ana. 		Dec 2028
4 Rev. Ana.
3 EPS Ana.
Revenue
839.69B
est: 819.13B (+2.5%)
883.92B
est: 811.98B (+8.9%)
960.31B
est: 878.06B (+9.4%)
1.03T
est: 918.97B (+12.2%)
1.11T
est: 1.01T (+10.2%)
1.06T
est: 954.27B (+10.6%)
1.15T
est: 1.08T (+6.6%)
1.28T
est: 1.21T (+5.9%)
1.38T
est: 1.26T (+8.9%)
1.42T
est: 1.35T (+5.7%)
1.57T
est: 1.53T (+2.6%)
1.53T
1.48T – 1.58T
-0.2% YoY
1.65T
1.53T – 1.87T
+8.1% YoY
1.79T
1.69T – 1.94T
+8.2% YoY
EBITDA
73.13B
est: 63.08B (+15.9%)
59.00B
est: 62.53B (-5.6%)
83.19B
est: 67.62B (+23.0%)
58.96B
est: 70.77B (-16.7%)
72.05B
est: 77.81B (-7.4%)
62.94B
est: 73.48B (-14.4%)
69.07B
est: 83.27B (-17.0%)
85.12B
est: 93.09B (-8.6%)
164.91B
est: 97.29B (+69.5%)
112.52B
est: 334.00B (-66.3%)
245.78B
est: 380.07B (-35.3%)
379.19B
368.13B – 392.32B
-0.2% YoY
410.05B
378.95B – 463.06B
+8.1% YoY
443.72B
419.83B – 481.26B
+8.2% YoY
EBIT
51.15B
est: 35.67B (+43.4%)
32.33B
est: 35.36B (-8.6%)
44.40B
est: 38.24B (+16.1%)
8.97B
est: 40.02B (-77.6%)
33.44B
est: 44.00B (-24.0%)
23.64B
est: 41.56B (-43.1%)
88.73B
est: 47.09B (+88.4%)
47.11B
est: 52.64B (-10.5%)
121.12B
est: 55.02B (+120.1%)
63.54B
est: 291.10B (-78.2%)
195.51B
est: 331.25B (-41.0%)
330.48B
320.84B – 341.92B
-0.2% YoY
357.38B
330.27B – 403.58B
+8.1% YoY
386.72B
365.90B – 419.45B
+8.2% YoY
Net Income
42.93B
est: 46.45B (-7.6%)
26.97B
est: 31.55B (-14.5%)
31.58B
est: 37.03B (-14.7%)
-15.15B
est: 24.10B (-162.9%)
22.01B
est: 21.38B (+2.9%)
12.75B
est: -2.61B (+588.7%)
24.51B
est: 27.24B (-10.0%)
42.24B
est: 70.60B (-40.2%)
121.74B
est: 107.25B (+13.5%)
24.73B
est: 65.90B (-62.5%)
195.86B
est: 163.24B (+20.0%)
138.89B
108.74B – 195.29B
-14.9% YoY
173.43B
137.75B – 248.37B
+24.9% YoY
234.27B
217.87B – 260.04B
+35.1% YoY
SGA
120.01B
est: 170.79B (-29.7%)
131.59B
est: 169.30B (-22.3%)
145.13B
est: 183.07B (-20.7%)
167.90B
est: 191.60B (-12.4%)
215.24B
est: 210.68B (+2.2%)
207.75B
est: 198.96B (+4.4%)
215.20B
est: 225.45B (-4.5%)
245.42B
est: 252.04B (-2.6%)
383.42B
est: 263.41B (+45.6%)
268.19B
est: 278.11B (-3.6%)
294.89B
est: 316.47B (-6.8%)
315.74B
306.53B – 326.67B
-0.2% YoY
341.44B
315.53B – 385.57B
+8.1% YoY
369.47B
349.58B – 400.73B
+8.2% YoY
EPS
4,160.00
est: 4,036.83 (+3.1%)
2,613.00
est: 2,742.40 (-4.7%)
3,060.00
est: 3,218.50 (-4.9%)
-1,468.08
est: 2,094.80 (-170.1%)
2,132.18
est: 1,857.95 (+14.8%)
1,196.00
est: -226.82 (+627.3%)
2,226.87
est: 2,367.53 (-5.9%)
3,815.95
est: 6,135.67 (-37.8%)
10,656.00
est: 9,321.03 (+14.3%)
2,149.85
est: 5,687.04 (-62.2%)
17,021.00
est: 14,088.04 (+20.8%)
11,987.09
9,384.40 – 16,854.61
-14.9% YoY
14,967.79
11,887.90 – 21,434.88
+24.9% YoY
20,218.20
18,803.21 – 22,442.24
+35.1% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-28 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-27 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-26 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-22 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-21 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-20 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-19 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-18 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-15 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-05-14 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-05-13 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-12 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-11 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-08 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-07 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-06 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-05-04 A 4/5 5/5 5/5 5/5 1/5 4/5 3/5
2026-04-30 A 4/5 5/5 5/5 5/5 1/5 4/5 3/5
2026-04-29 A 4/5 5/5 5/5 5/5 1/5 4/5 3/5
2026-04-28 A 4/5 5/5 5/5 5/5 1/5 4/5 3/5
2026-04-27 A 4/5 5/5 5/5 5/5 1/5 4/5 3/5
2026-04-24 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-04-23 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-04-22 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-04-21 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-04-20 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-04-17 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-04-16 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5
2026-04-15 A 4/5 5/5 5/5 5/5 1/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-49.38B
OE per share TTM
-4,285.10
Owner's Yield
-3.26%
Maintenance CapEx ratio
253.19%
Maint CapEx / Avg PPE
40.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
113.21M
Shares Outstanding
11.51M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chang-Jae Lee Chief Executive Officer & Executive Director 650M male
Seongsoo Park Chief Executive Officer & Executive Director 650M male
Eunkyeong Park Executive Director — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic